Licensing · Türkiye · Announced 10 Apr 2026
Hybio Pharmaceutical → MCG Pharma
Chinese peptide maker Hybio has licensed exclusive Turkish rights for its liraglutide and semaglutide injections to MCG Pharma, positioning for Türkiye's GLP-1 generics market.
Parties: Shenzhen Hybio Pharmaceutical Co., Ltd. (China) → MCG Pharma İlaç Sanayi ve Ticaret Ltd. Şti. (Turkey)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Türkiye
- Therapeutic area
- Metabolic / Diabetes
- Assets
- Liraglutide injection; Semaglutide injection
- Announced
- 10 Apr 2026
Our analysis
Why this matters
Shenzhen Hybio Pharmaceutical has granted MCG Pharma exclusive rights to commercialize its liraglutide and semaglutide injections and related products in Türkiye. The two companies will work together on registration, market access, localization and post-launch support.
GLP-1 receptor agonists are the most valuable small-volume molecules in the market, and the first wave of semaglutide generics is arriving in markets where compound protection is ending. Chinese peptide manufacturers, with large-scale peptide synthesis capacity, are racing to lock in local partners market by market. Türkiye — a large, price-regulated market with strong domestic commercial players — is an obvious target.
The full analysis is free to read with a work email on this page.